Related Experiment Videos
[Ganglioside GM1 in early strokes]
A Kuczyńska-Zardzewiały1, J Kruszewska, W Lechowicz
1Kliniki Chorób Naczyniowych Układu Nerwowego, Instytutu Psychiatrii i Neurologii, Warszawie.
Neurologia I Neurochirurgia Polska
|September 1, 1994
Summary
This study found that ganglioside GM1 treatment did not improve outcomes for ischemic stroke patients compared to standard care. No significant differences in mortality, neurological state, or general fitness were observed after 30 days.
Area of Science:
- Neurology
- Clinical Trials
Background:
- Ischemic stroke is a leading cause of disability.
- Early intervention is crucial for improving patient outcomes.
- Ganglioside GM1 is a potential therapeutic agent for neurological recovery.
Purpose of the Study:
- To compare the efficacy of ganglioside GM1 (Sygen) plus typical treatment versus typical treatment alone in patients with ischemic stroke.
- To evaluate the impact of ganglioside GM1 on mortality, neurological status, and general fitness.
Main Methods:
- A randomized controlled trial involving 98 patients with confirmed ischemic stroke within 48 hours of onset.
- Patients received either typical treatment or typical treatment plus 100 mg daily of ganglioside GM1 for 30 days.
- Neurological state assessed using the Canadian Neurological Scale (CNS) and general fitness by the Ranking Classification (RS).
Main Results:
- No significant differences were found between the ganglioside GM1 group and the control group in mortality rates after 30 days.
- Mean survival time, neurological state (CNS scores), and general fitness (RS scores) showed no improvement with ganglioside GM1 treatment.
- The study did not confirm a beneficial influence of Sygen treatment on ischemic stroke outcomes.
Conclusions:
- Ganglioside GM1 treatment did not demonstrate a significant benefit in improving outcomes for patients with ischemic stroke within the study's parameters.
- Further research may be needed to explore potential therapeutic roles of gangliosides in stroke, possibly with different formulations or patient populations.
- Current evidence does not support the use of Sygen for routine treatment of ischemic stroke.